Key Takeaways
- • Path Robotics, a Columbus, Ohio-based manufacturing robotics developer, raised $300m in Series E funding at a $2.45b post-money valuation, led by Georgian with participation from D. E. Shaw Ventures and NAVER Ventures.
- • Mubadala Capital agreed to acquire a minority interest in LSV Advisors, a New York-based secondaries manager focused on the middle market.
- • Zacua Ventures, an SF-based venture capital firm, raised $135m for its second fund.
- • Blue J, a Toronto-based tax research and advisory platform, raised US$176m in Series E funding at a $700m-plus valuation, led by JMI Equity.
- • MaxCyte (Nasdaq: MXCT) agreed to acquire Akron BioProducts from Arcline for $151.8m.
Summary
Path Robotics, a Columbus, Ohio-based developer of manufacturing robotics, raised $300m in Series E funding at a $2.45b post-money valuation, according to Axios. Georgian led the round, joined by D. E. Shaw Ventures, NAVER Ventures and existing investors Addition, Drive Capital, IronArc Ventures, Tiger Global and Yamaha Motor Ventures.
In private equity, Mubadala Capital agreed to acquire a minority interest in LSV Advisors, a New York-based secondaries manager focused on the middle market. The deal terms were not disclosed in the summary.
In fundraising, Zacua Ventures, a San Francisco-based venture capital firm, closed $135m for its second fund. Proximal Ventures, a California-based biotech investor, raised $27.5m for its debut fund, with LPs including SignalFire, Kleiner Perkins, Domino Lane and Bertelsmann Healthcare Investments.
Other venture rounds included Blue J, a Toronto-based tax research and advisory platform, which raised US$176m in Series E funding at a valuation above $700m, led by JMI Equity; and Graphon Labs, an SF-based agentic AI lab, which raised $35m in Series A funding led by RRE Ventures. In liquidity activity, MaxCyte (Nasdaq: MXCT) agreed to acquire Boca Raton, Fla.-based reagent supplier Akron BioProducts from Arcline for $151.8m.
In private equity, Mubadala Capital agreed to acquire a minority interest in LSV Advisors, a New York-based secondaries manager focused on the middle market. The deal terms were not disclosed in the summary.
In fundraising, Zacua Ventures, a San Francisco-based venture capital firm, closed $135m for its second fund. Proximal Ventures, a California-based biotech investor, raised $27.5m for its debut fund, with LPs including SignalFire, Kleiner Perkins, Domino Lane and Bertelsmann Healthcare Investments.
Other venture rounds included Blue J, a Toronto-based tax research and advisory platform, which raised US$176m in Series E funding at a valuation above $700m, led by JMI Equity; and Graphon Labs, an SF-based agentic AI lab, which raised $35m in Series A funding led by RRE Ventures. In liquidity activity, MaxCyte (Nasdaq: MXCT) agreed to acquire Boca Raton, Fla.-based reagent supplier Akron BioProducts from Arcline for $151.8m.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.